CYTR - CytRx Corporation
| Previous Close | 0.3603 |
| Open | 0.3592 |
| Bid | 0.3550 x 600 |
| Ask | 0.5845 x 100 |
| Day's Range | 0.3592 - 0.3800 |
| 52 Week Range | 0.3400 - 1.0000 |
| Volume | 782,338 |
| Avg. Volume | 4,481,610 |
| Market Cap | 60.38M |
| Beta | 1.64 |
| PE Ratio (TTM) | -0.89 |
| EPS (TTM) | -0.41 |
| Earnings Date | Nov 7, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- PR Newswire•5 days ago
CytRx Corporation Announces Outcome of Nasdaq Hearing
On or before October 30, 2017, the Company shall inform the Panel that is has received stockholder approval to implement a reverse stock split in a ratio of 1 for 6 shares. On or before November 15, 2017, the Company must evidence a closing bid price of $1.00 or more for a minimum of ten prior consecutive trading days.
- PR Newswire•9 days ago
CytRx Corporation Highlights Inclusion of Aldoxorubicin in Pending Upcoming Clinical Trial Submissions Planned By Licensee NantCell, Inc.
LOS ANGELES , Oct. 12, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee ...
- PR Newswire•17 days ago
Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact Firm
Shareholder Rights Law Firm Johnson Fistel, LLP today announced that it is investigating whether certain officers or directors of NantKwest, Inc. (NK) ("NantKwest") violated federal or state laws. On September 20, 2017, a federal court denied a motion to dismiss a securities fraud class action filed against the company and certain executives.
- PR Newswire•17 days ago
Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock Split
LOS ANGELES, Oct. 4, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Institutional Shareholder Services, Inc. (ISS), the leading global independent proxy advisory firm, issued a report on September 28, 2017, recommending that CytRx stockholders vote "FOR" the proposed reverse stock split at the upcoming special meeting of stockholders scheduled for October 17, 2017 at 10:00 a.m. PT. ISS is the most prominent independent proxy voting and corporate governance advisory firm, and its recommendations are relied upon by institutional investment firms, mutual funds and other fiduciaries globally. ISS' experienced research team provides comprehensive proxy analyses and complete vote recommendations for approximately 40,000 meetings annually in around 117 markets worldwide.
- PR Newswire•19 days ago
CytRx Corporation Provides Business Update and Highlights Future Plans
LOS ANGELES, Oct. 2, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today provided a business update and highlighted the Company's future plans. During 2017, CytRx has made significant strides in advancing its lead oncology asset aldoxorubicin from a late-stage clinical asset to a partnered, pre-New Drug Application (NDA) candidate in the U.S. In July 2017, CytRx announced a strategic licensing transaction with NantCell, Inc., for the global rights to aldoxorubicin. Dr. Patrick Soon-Shiong, the CEO and founder of NantCell, developed, obtained regulatory approval for, and commercialized Abraxane®, another albumin-mediated cytotoxic agent which currently generates approximately $1B in annual sales. CytRx believes that Dr. Soon-Shiong's track record and expertise with albumin-mediated agents will prove invaluable as NantCell works to obtain regulatory approval for aldoxorubicin, with the goal of commercialization thereafter.
- PR Newswire•last month
Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the Proposed Reverse Stock Split
LOS ANGELES, Sept. 21, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Glass Lewis & Co. has recommended that CytRx stockholders vote "FOR" the proposed reverse stock split at the upcoming special meeting of stockholders scheduled for October 17, 2017 at 10:00 a.m. PT. Glass Lewis is widely recognized as one of the leading independent proxy voting and corporate governance advisory firms, and its recommendations are relied upon by thousands of major institutional investment firms, mutual funds and other fiduciaries throughout the United States.
- PR Newswire•last month
CytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting
LOS ANGELES, Sept. 13, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that based on feedback the company has received from stockholders, it has amended its definitive proxy statement with the Securities and Exchange Commission ("SEC") to include a 1-for-6 reverse stock split of the Company's authorized common and preferred stock. CytRx's previous proxy statement dated September 5, 2017, had a proposal for a 1-for-6 reverse stock split for its issued and outstanding common stock and a 50% reduction in the authorized shares. CytRx believes that a reverse stock split will enable it to regain compliance with NASDAQ's $1.00 minimum bid price requirement and maintain its listing on the NASDAQ Capital Market. CytRx currently meets all other NASDAQ listing requirements.
- PR Newswire•2 months ago
CytRx Corporation Files Definitive Proxy Statement for Upcoming Special Meeting
LOS ANGELES , Aug. 30, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has filed a definitive ...
- PR Newswire•2 months ago
CytRx Corporation Announces Receipt of NASDAQ Listing Determination
LOS ANGELES, Aug. 24, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that, as anticipated, on August 22, 2017, it received a letter from the Listing Qualifications Staff (the "Staff") of the NASDAQ Stock Market LLC ("NASDAQ") indicating the Company's failure to regain compliance with the minimum $1.00 bid price requirement by August 21, 2017, which will serve as a basis for delisting the Company's common stock from The NASDAQ Capital Market. The Company's common stock will continue to trade on NASDAQ under the symbol "CYTR" pending the conclusion of the hearing process. CytRx remains focused on the development of its ultra-high potency oncology drug conjugates based on its LADR™ technology platform. Last month, CytRx announced that it entered into an exclusive license with NantCell, Inc. for worldwide rights in all indications for aldoxorubicin, its lead albumin-binding drug conjugate. CytRx received a strategic investment of $13 million at $1.10 per common share. CytRx is also eligible to receive up to $343 million in milestone payments upon the achievement of regulatory approvals and commercial milestones. Additionally, CytRx will receive increasing double-digit royalties for sales of aldoxorubicin for soft tissue sarcomas and mid to high single digit royalties for sales in other indications.
- PR Newswire•2 months ago
CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting
LOS ANGELES, Aug 21, 2017 /PRNewswire/ -- CytRx Corporation (CYTR) ("CytRx or "the Company"), a biopharmaceutical research and development company specializing in oncology, announced that it has filed a preliminary proxy statement with the Securities and Exchange Commission ("SEC") in connection with a planned special meeting of stockholders to authorize the Board of Directors to effect a reverse stock split of the Company's common stock, if deemed necessary. A reverse stock split may enable the Company to regain compliance with NASDAQ's $1.00 minimum bid price requirement and maintain its listing on the NASDAQ Capital Market. CytRx's intent is to continue to be listed on the NASDAQ Capital Market. In addition to sustaining a NASDAQ listing, the Company believes a higher share price resulting from a reverse stock split will help enlarge the shareholder base by expanding its appeal to institutional investors and as a result enhance long-term stockholder value.
- ACCESSWIRE•2 months ago
CytRx New Drug Development Agreement Brings Cash and Experience
NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies issued a comprehensive report ...
- Associated Press•3 months ago
CytRx reports 2Q loss
The Los Angeles-based company said it had a loss of 10 cents per share. Losses, adjusted for non-recurring costs, came to 7 cents per share. The company's shares closed at 80 cents. A year ago, they were ...
- PR Newswire•3 months ago
CytRx Reports Second Quarter 2017 Financial Results
LOS ANGELES , Aug. 3, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ...
GuruFocus.com•3 months ago4 Biotech Stocks to Watch This Quarter
Biotech could easily continue to grow as long-term trends remain in place
- ACCESSWIRE•3 months ago
Today's Research Reports on Stocks to Watch: CytRx Corporation and ImmunoGen
NEW YORK, NY / ACCESSWIRE / July 31, 2017 / CytRx Corporation was one of the most active stocks on the NASDAQ this past Friday as well as one of the biggest gainers. The stock soared after announcing it ...
- PR Newswire•3 months ago
CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic
NantCell to Expand the Development of Aldoxorubicin into Multiple Tumor Types in Combination with Immuno-Oncology and Cell-Based Therapies CytRx will receive up to $356 Million in a Strategic Investment ...
- Investopedia•4 months ago
Penny Stocks to Watch for June 2017 (CYTR, DELT)
These ten penny stocks trading on U.S. public exchanges could gain substantial ground in 2017.
- PR Newswire•4 months ago
CytRx Announces Reshaping of Clinical and Regulatory Executive Team
LOS ANGELES, June 13, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Shanta Chawla, M.D., who ...
- Accesswire•4 months ago
Today's Research Reports on Stocks to Watch: CytRx and Hydrogenics Corporation
NEW YORK, NY / ACCESSWIRE / June 9, 2017 / CytRx's shares saw a big gaining day yesterday after the company announced a big regulatory pathway update about aldoxorubicin, a tumor-targeted doxorubicin conjugate ...
- TheStreet.com•5 months ago
Goodbye CytRx, Your Game Is Over
Hope springs eternal, until it's dashed on the rocks and buried at sea.
- Investopedia•5 months ago
Penny Stocks to Watch for June 2017
These ten penny stocks trading on U.S. public exchanges could gain substantial ground in June 2017 and the coming months.
- Accesswire•5 months ago
Today's Research Reports on Stocks to Watch: Endocyte and CytRx
NEW YORK, NY / ACCESSWIRE / May 31, 2017 / While still not anywhere the highs of 2015's boom, the Biotech Industry has shown some signs of a comeback in 2017. After a dismal 2016, the iShares NASDAQ Biotechnology ...
- Benzinga•5 months ago
The Most Notable Abstracts Released Ahead Of ASCO 2017
The American Society of Clinical Oncology, or ASCO, has scheduled its annual meeting on June 2–6, 2017, at McCormick Place, Chicago. The five-day event has Conquer Cancer Foundation as its lead sponsor. ...
- Accesswire•5 months ago
Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx
NEW YORK, NY / ACCESSWIRE / May 19, 2017 / Despite the recent sell-off triggered by the recent health-care bill that is meant to take the place of the Affordable Care Act, the Biotech Industry has continued ...
- PR Newswire•5 months ago
CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting
LOS ANGELES, May 17, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of two abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago. The first is an oral presentation featuring updated and more detailed results from the Company's global Phase 3 clinical trial evaluating aldoxorubicin versus investigator's choice in patients with relapsed and refractory soft tissue sarcomas (STS). The other is a poster presentation describing updated data from an ongoing Phase 1/2 clinical trial combining aldoxorubicin with ifosfamide/mesna (I-M) in first- and second-line STS.